Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Lorcaserin XR (Kawashima vs Zofingen)
NCT03627936Phase 1Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Aug 2018
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of lorcaserin in obesity (2 arms), sponsored by Eisai Co., Ltd. Primary endpoints: Maximum Observed Plasma Concentration at 96 hours, Area under the concentration-time curve from zero time to time of last quantifiable concentration at 96 hours and 4 more. Started Aug 2018; status: completed.
02
Drugs
lorcaserin
03
Conditions
obesity
Beyond the preview
Go deeper on NCT03627936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03627936.